Mednet Logo

Is there a rationale for treating medically inoperable stage I-III breast cancer patients with RT alone?

My understanding is that if someone isn’t medically operable, the default is to offer systemic therapy palliatively because breast cancer is thought of as a surgical disease (even though RT can be safely delivered to curative doses because there aren’t adjacent critical structures). Is there any data (or anecdotal experience) to support treating these patients with radiation alone?
4 Answers
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Beth Israel Deaconess Medical Center
Answered on

We treated stage III patients with "radical radiotherapy" with or without chemotherapy when I was a resident in the early 1980s, since they were considered SURGICALLY inoperable then. However, very high doses were needed (75-80 Gy to the primary using external beam followed by interstitial implants)...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Allegheny Health Network, Pittsburgh
Answered on

There are two situations I consider RT (without surgery) in these situations:

  1. Palliation - if the mass begins to grow and involves skin or deep chest wall, we can offer palliative dose RT.
  2. Borderline operable cases - in these scenarios, we often start with systemic therapy. If still borderline, we ...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · The Oregon Clinic-Radiation Oncology West
Answered on

For inoperable patients or those who refuse surgery, there are multiple case series that report reasonable results with radiotherapy +/- systemic therapy without surgery. Meaningful definitive local control can be achieved. Higher doses are better, but not always feasible for large tumor volumes. An...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Kingston Health Sciences Centre
Answered on

There is a cohort of patients, medically inoperable due to multiple comorbidities and hence not systemic therapy candidates too, we have been offering SBRT with good outcomes, off trial.

There is an in-house trial too at Sunnybrook, breast SBRT trial (dose escalation/toxicity endpoints) from which w...

Join for free or sign in to see the full answer